Disitamab Vedotin in the Treatment With HER2- Expression, Subjects With Locally Advanced or Metastatic Castration-resistant Prostate Cancer

This study is testing disitamab vedotin, a targeted drug, in patients with prostate cancer that has spread and is no longer responding to hormone-blocking treatments (called castration-resistant prostate cancer). The trial focuses on patients whose tumors express the HER2 protein. **You may be eligible if...** - You are 18 or older with confirmed prostate adenocarcinoma - Your cancer has spread locally or to other parts of the body - Your cancer is castration-resistant (progressing despite hormone therapy) - Your tumor expresses HER2 protein on testing - Your PSA has been rising or imaging shows disease progression **You may NOT be eligible if...** - Your cancer does not express HER2 - You have not yet had hormone therapy for advanced prostate cancer - Your overall health is too poor for treatment - You have severe heart, liver, or kidney problems Talk to your doctor to see if this trial is right for you.